Biogen And Eisai Co., Announced That The US Food And Drug Administration Has Extended The Review Period By Three Months For The Supplemental Biologics License Application For A Once-weekly Lecanemab-irmb Subcutaneous Injection As A Starting Dose For The Treatment Of Early Alzheimer's Disease